<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655993</url>
  </required_header>
  <id_info>
    <org_study_id>00746</org_study_id>
    <nct_id>NCT00655993</nct_id>
  </id_info>
  <brief_title>Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)</brief_title>
  <official_title>Effect of Statin Therapy on C-Reactive Protein Levels in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Loma Linda Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Loma Linda Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in
      COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation,
      which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and
      independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering
      drugs that decrease mortality from cardiovascular disease and stroke. In addition, they have
      anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower C-reactive
      protein by the ability to reduce the production of interleukin (IL)-6, the cytokine that
      activates the acute phase CRP response.

      Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and
      ET-1 in COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum CRP levels</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>40 mg po daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically optimized COPD patients

          -  Age 40-79 years.

          -  serum CRP levels &gt;3mg/l

        Exclusion Criteria:

          -  Current smoker

          -  COPD exacerbation in the last 2 months.

          -  Active hepatic or severe renal dysfunction.

          -  connective tissue disease, chronic inflammatory disease, malignancy, any acute
             illness, leukocytosis (&gt;10,000 white blood cells) or thrombocytosis (&gt;450,000
             platelets).

          -  Recent h/o myocardial infarction, angina in the last 6 months.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lennard Specht, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Loma Linda Health Care System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hemal J. Parekh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Loma LInda Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D. Anholm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Loma Linda Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hemal J. Parekh, M.D.</last_name>
    <phone>909-825-7084</phone>
    <phone_ext>6098</phone_ext>
    <email>hemalp6@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lennard Specht, M.D.</last_name>
    <phone>909-825-7084</phone>
    <phone_ext>6098</phone_ext>
    <email>norman.specht@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Loma Linda Health Care System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lennard Specht, M.D.</last_name>
      <phone>909-825-7084</phone>
      <phone_ext>6098</phone_ext>
      <email>norman.specht@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>James Anholm, M.D.</last_name>
      <phone>909-825-7084</phone>
      <phone_ext>6098</phone_ext>
      <email>james.anholm@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <last_update_submitted>April 9, 2008</last_update_submitted>
  <last_update_submitted_qc>April 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lennard Specht, M.D.</name_title>
    <organization>VA Loma Linda Health Care System</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Inflammation</keyword>
  <keyword>CRP levels</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

